Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of June 28, 2013:
- Total Issued Shares: 5,410,255,226 Ordinary Shares of 25p each.
- Treasury Shares: 497,039,512 Ordinary Shares.
- Total Voting Rights: 4,913,215,714.
No material changes in financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,913,215,714) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (497,039,512) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.